AUGSBURG, Germany

Markus Reinbold

This inventor holds 1 USPTO granted patent. Top assignee: Technische Universität München. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Markus Reinbold. Retrieved from https://idiyas.com/inventor/markus-reinbold

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Markus Reinbold

Introduction

Markus Reinbold is a notable inventor based in Augsburg, Germany. He has made significant contributions to the field of biochemistry, particularly in the area of terpene synthases. His work has implications for the production of valuable compounds used in various applications.

Latest Patents

Markus Reinbold holds a patent titled "Modified Terpene Synthases and Their Use for Production of Pseudopterosin Intermediates and/or Pseudopterosins." This patent highlights his innovative approach to synthesizing complex organic molecules, which can be crucial for pharmaceutical and cosmetic industries.

Career Highlights

Reinbold is affiliated with the Technische Universität München, where he engages in research and development. His academic background and ongoing research contribute to advancements in biochemistry and molecular biology.

Collaborations

He has collaborated with notable colleagues such as Marion Ringel and Thomas Brück, enhancing the scope and impact of his research through teamwork and shared expertise.

Conclusion

Markus Reinbold's work exemplifies the intersection of innovation and practical application in science. His contributions continue to influence the field and pave the way for future advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…